EMA Revoked: Lartruvo (olaratumab) — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA revoked the marketing authorization for Larotruvo (olaratumab) by Eli Lilly Nederland B.V., effectively withdrawing approval for its use in sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• Lartruvo (olaratumab)

Snippet

Status: Revoked. Therapeutic area: Sarcoma. MAH: Eli Lilly Nederland B.V.. Decision date: 11/01/2018. Conditional approval. Accelerated assessment